ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today its expanded and fully integrated portfolio of resuscitation and acute critical care technologies and data management solutions will be on display during the American Heart Association (AHA) 2016 Annual Conference in Booth 1639 November 13-15 in New Orleans.
ZOLL is the market leader in hospitals for defibrillators. Its R Series® Monitor/Defibrillator offers continual waveform capnography, which is an American Heart Association (AHA) Class I recommendation for monitoring ET tube placement. It is the only defibrillator to offer both mainstream and sidestream capnography on one device. The R Series utilizes two proprietary technologies to help clinical staff consistently deliver high-quality CPR with minimal pause time, and post-event provides intuitive data management software programs to assist with critical quality improvements.
Unmatched Pediatric Capabilities
ZOLL’s OneStep™ Pediatric CPR Electrodes are used in a majority of the top 25 U.S. News and World Report pediatric cardiology hospitals. These are the only electrodes on the market with a built-in CPR sensor that displays the depth and rate of chest compressions during CPR on young children up to 8 years of age. The first of their kind, these electrodes provide optimal support for pediatric resuscitation when paired with the ZOLL R Series. The OneStep Pediatric CPR Electrodes can be used for monitoring, pacing, and defibrillation, as well as displaying CPR quality on the R Series CPR Dashboard™.
Unsurpassed CPR Support
Increasing the quality of CPR has been an ongoing commitment of ZOLL’s since 2002, when it was the first to introduce real-time CPR feedback in its AED Plus®. Today, all ZOLL defibrillators, including the AED Plus, the AED Pro®, the R Series, and the X Series®, feature Real CPR Help® audio and visual feedback for the correct rate, depth, release, and tracking of idle time. Real CPR Help is the only CPR feedback technology that, in combination with training, has been shown to impact survival to discharge, as demonstrated in published research.1
ZOLL’s commitment to high-quality CPR is also evident in the company’s suite of tools for optimal resuscitation response, which includes See-Thru CPR® as well as EtCO2 monitoring. ZOLL’s proprietary See-Thru CPR technology, which minimizes the duration of pauses in CPR by enabling rescuers to see an organized underlying rhythm, is available on the R Series, the X Series, and the AED Pro.
Additionally, the 2015 AHA Guidelines recommend automated CPR devices, such as the AutoPulse® Resuscitation System, as Class IIb, citing their role in performing high-quality CPR when manual CPR is difficult to achieve, such as during patient transport or in the cath lab.
The 2015 Guidelines expand the recommendation for post-ROSC cooling to include all comatose patients, regardless of rhythm or location of arrest. ZOLL’s Thermogard XP® Temperature Management System is uniquely capable of helping hospitals achieve precise temperature control for any recommended target between 32°C and 36°C.
Also unique to ZOLL is the LifeVest® Wearable Defibrillator, which is worn by patients at risk for sudden cardiac death (SCD), providing protection during their changing condition and while permanent SCD risk has not been established. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is lightweight and easy to wear and allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
New to ZOLL’s expanding product portfolio is the Eagle II™ portable critical care ventilator, which is used in the management of patients ≥5 kg with acute or chronic respiratory failure. It can be used inside the hospital, during transport, and in MRI suites. The Eagle II is designed to be durable and lightweight, with a 10-hour battery and multiple modes of ventilation, including non-invasive ventilation.
Scientific Assembly Presentations
An education grant from ZOLL helps to underwrite the AHA Resuscitation Science Symposium (ReSS), an international forum for scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury. Seventeen scientific presentations related to ZOLL products and technology are scheduled to be presented during ReSS. Key presentations:
• Liang Wei, BS, will present “Detection of Spontaneous Pulse Using Acceleration Signals Acquired from CPR Feedback Sensor in Porcine Model of Cardiac Arrest,” Saturday, November 12 at 1:47-1:55 pm. in Great Hall C-D. Poster 277.
• Chingping Wan, MD, ZOLL, will present “In-Hospital VT/VF Arrest by Time and Location When Using a Wearable Cardioverter Defibrillator,” Saturday, November 12 at 1:55-2:03 pm. in the Great Hall C-D. Presentation 130.
• Prof. Esteban Lopez de Sá will present “A Pilot Multicenter Randomized Trial on the Effectiveness of Different Levels of Cooling in Comatose Survivors of Out-of-hospital Cardiac Arrest. FROST-I trial,” Saturday, November 12 at 5:15-5:30 pm. Presentation 90.
• Annemarie Silver, PhD, ZOLL, will present “Clinical Feedback from Prehospital Use of a Novel Traumatic Brain Injury Dashboard,” Sunday, November 13 at 8:32-8:40 am. in Great Hall C-D. Poster 277.
• Prof. Dr. Ruth Strasser, University of Dresden, Germany, will present “Original Research Article: Experience with Wearable Defibrillator” during the “Groundbreaking Studies in the Practice of Cardiovascular Medicine: Circulation Editors' Choices” session, Sunday, November 13 at 10:00-10:10 am. in Room 224.
• Yusuke Kondo, MD, PhD, Chiba University Graduate School of Medicine, Japan, will present “Efficacy and Cost-Effectiveness of Wearable Cardioverter Defibrillator as a Lifesaving-Bridge Therapy for Decision in High Risk Patients of Sudden Arrhythmic Death: 3-Year Follow-Up Result,” Sunday, November 13 at 3:45-5:00 pm. in the Science and Technology Hall. Presentation S5260.
• Chengcheng Hu, PhD, will present “Differential Correlation of EtCO2 and CPR Quality between Cardiac and Respiratory Etiology in Out-of-Hospital Cardiac Arrest,” Monday, November 14 at 8:24-8:32 am. in Great Hall C-D. Poster 315.
A listing and schedule of the ZOLL-related presentations is available at zoll.com/aha-presentations2016/.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.
1. Bobrow BJ, et al. Ann Emerg Med. 2013 Jul;62(1):47 56.e1. Epub 2013 Mar 7.
Copyright © 2016 ZOLL Medical Corporation. All rights reserved. AED Plus, AED Pro, AutoPulse, CPR Dashboard, Eagle II, LifeVest, OneStep, Real CPR Help, R Series, See-Thru CPR, Thermogard XP, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.